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Abstract: Background: Dp71 is the most abundant dystrophin (DMD) gene product in the nervous
system. Mutation in the Dp71 coding region is associated with cognitive disturbances in Duchenne
muscular dystrophy (DMD) patients, but the function of dystrophin Dp71 in tumor progression
remains to be established. This study investigated Dp71 expression in glioblastoma, the most common
and aggressive primary tumor of the central nervous system (CNS). Methods: Dp71 expression
was analyzed by immunofluorescence, immunohistochemistry, RT-PCR, and immunoblotting in
glioblastoma cell lines and cells isolated from human glioblastoma multiforme (GBM) bioptic
specimens. Results: Dp71 isoform was expressed in normal human astrocytes (NHA) cell lines and
decreased in glioblastoma cell lines and cells isolated from human glioblastoma multiforme bioptic
specimens. Moreover, Dp71 was localized in the nucleus in normal cells, while it was localized
into the cytoplasm of glioblastoma cells organized in clusters. We have shown, by double labeling,
that Dp71 colocalizes with lamin B in normal astrocytes cells, confirming the roles of Dp71 and lamin
B in maintaining nuclear architecture. Finally, we demonstrated that decreased Dp71 protein in cells
isolated from human bioptic specimens was inversely correlated with the Ki-67 tumor proliferative
index. Conclusion: A decreased Dp71 expression is associated with cancer proliferation and poor
prognosis in glioblastoma.
Keywords: Dp71; glioblastoma; lamin B; tumor progression
1. Introduction
Dp71 is the most abundant product of the dystrophin (DMD) gene in the adult brain [1]. The DMD
gene consists of 79 exons and seven alternative promoters used to express tissue-specific dystrophin
isoforms. Dp71 is a 71 kDa protein transcribed from a promoter located in intron 62 [2]. It has
been reported that mutations in the Dp71 coding region are associated with cognitive impairment in
Duchenne muscular dystrophy (DMD) patients [3–5]. Furthermore, the expression of Dp71 is involved
in the development of the nervous system [6], and current Dp71 research identifies its involvement
in ion and water homeostasis, cell signaling, cell adhesion, and nuclear architecture [2,7–10]. Little
data are available concerning the role of Dp71 in tumor progression. In gastric cancer, Dp71–lamin
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complexes were found to have tumor suppressive effects [11]. In addition, knockdown of Dp71 was
found to reduce malignancy of a lung adenocarcinoma cell line [12]. Recently, Rani et al. [13] have
identified six splice variants of Dp71 in glioblastoma cells, with Dp71b being the most abundant.
In this study, we analyzed Dp71 and lamin B expression in glioblastoma multiforme (GBM),
the most common and aggressive primary tumor of the central nervous system (CNS), which is
characterized by rapid proliferation, metastatic capacity-enhanced angiogenesis, and resistance to
treatment [14–16].
We demonstrated using immunofluorescence, immunohistochemistry, RT-PCR, and immunoblotting
that Dp71 isoform is expressed in normal human astrocytes (NHA) cell lines and decreased in
glioblastoma cell lines and in cells isolated from human GBM bioptic specimens. Moreover, Dp71 was
localized in the nucleus of normal cells, while it was localized in the cytoplasm of glioblastoma cells
and organized in clusters. We have shown, by double labeling, that Dp71 colocalizes with lamin B in
normal astrocytes cells, confirming the roles of Dp71 and lamin B in maintaining nuclear architecture.
Finally, we demonstrated that decreased Dp71 protein in cells isolated from human bioptic specimens
inversely correlated with the Ki-67 tumor proliferative index.
2. Results
2.1. Subcellular Reorganization of Dp71 Protein in Glioblastoma and Meningioma Cells and Interaction
between Dp71 and Lamin B in NHA Cells
We analyzed the expression of Dp71 protein in glioblastoma cells, including the U118MG cell line
and in glioblastoma cells obtained from three patients with GBM. We also analyzed Dp71 expression
in the HBL52 cell line (derived from transitional meningioma grade I) to evaluate the correlation of
Dp71 expression with the malignancy grade. All of the analyzed cell groups were compared with the
NHA cell line. A dual confocal immunofluorescence reaction of Dp71 and lamin B in glioma and NHA
cells was performed (Figure 1A–R). The results show that Dp71 protein was present in the nucleus of
NHA cells (Figure 1A,B,D) and colocalizes with lamin B in a nuclear envelope (Figure 1A,B yellow
arrow). The Dp71 protein pattern was different in glioblastoma and meningioma cells. The primary
glioblastoma cells (GLI1) and HBL52 cells show a Dp71 cytoplasmic expression with a formation of
clusters (Figure 1E,F,H,O,P,R black arrow) and no colocalization signal between Dp71 and lamin B
proteins was detected (Figure 1E–I,L–R). Moreover, Dp71 expression was reduced in U118MG and in
GLI1 (Figure 1I,L–R), while lamin B expression was increased in the U118MG cell line in association
with the increased size of the tumor cell nuclei (Figure 1I,L,M) Morphometric analysis confirmed a
meaningful reduction of Dp71 fluorescence intensity in U118MG and GLI1 cells, while Dp71 increased
in HBL52 cells compared to control NHA cells (Figure 1S). Lamin B was overexpressed only in the
U118MG cell line and lamin B/Dp71 dystrophin isoform (Dys) did not colocalize (Figure 1S).
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Figure 1. Lamin B (red) and Dp71 dystrophin isoform (Dys) (green) confocal dual 
immunofluorescence reaction in tumor (E,F,G,H,I,L,M,N,O,P,Q,R) and normal human astrocytes 
(NHA) (A,B,C,D) cells. Dys fluorescent signal decreases and localizes in the cytoplasm of U118MG 
(I,L,N) and the glioblastoma primary cell line (GLI1) (O,P,R) tumor cells compared with strong and 
diffused nuclear signal in the NHA control cells (A,B,D). An orange fluorescence signal 
corresponding to colocalization of lamin B and Dys is present in NHA cells (A,B yellow arrows). 
HBL52 meningioma cells (E,F,G,H) show a strong cytoplasmic and clustered Dys signal (E,F,H, white 
arrow) compared to the control cells (A,B,D). Lamin B red fluorescence increases in U118MG (L,M) 
Figure 1. Lamin B (red) and Dp71 dystrophin isoform (Dys) (green) confocal dual immunofluorescence
reaction in tumor (E–I,L–R) and normal human astrocytes (NHA) (A– ) cells. Dys fluorescent sign
decreases and lo aliz s in the cytoplas of U118MG (I,L,N) and the glioblastoma primary cell line (GLI1)
O,P,R) tumor cells compared with trong and diffused nuclear signal in the NHA c ntrol cells (A,B,D).
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An orange fluorescence signal corresponding to colocalization of lamin B and Dys is present in NHA
cells (A,B yellow arrows). HBL52 meningioma cells (E–H) show a strong cytoplasmic and clustered Dys
signal (E,F,H, white arrow) compared to the control cells (A,B,D). Lamin B red fluorescence increases in
U118MG (L,M) tumor cells compared to the NHA control cells (B,C). Morphometric analysis (S) shows
a significant reduction of Dys fluorescence intensity in U118MG and GLI1 tumor cells, a significant
increase of Dys expression in HBL52 meningioma cells, and a significant increase of lamin B expression
in U118MG cells compared to NHA cells. The fluorescence intensity of colocalization decreases in
tumor cells. (* p < 0.05, ** p < 0.01, *** p < 0.001—all groups vs. NHA group) Scale Bar: A–R 10 µm.
2.2. Decreased Dp71 and Increased Lamin B mRNA and Protein Expressions in U118MG Cell Line and in
Glioblastoma Cells Derived from GBM Patients
Western blot analysis was performed using total, cytoplasmic, and nuclear extract proteins
to determine Dp71 and lamin B protein levels and to quantify the difference in subcellular Dp71
expression in NHA, HBL52, and U118MG cell lines, and in glioblastoma primary cells (Figure 2A–C).
The Dp71 total expression level was significantly lower in U118MG and GLI1, and significantly higher
in HBL52 compared with the NHA control cell line. Moreover, Dp71 protein levels were decreased in
the nucleus and increased in the cytoplasm of HBL52, U118MG, and GLI1, compared to the control
(Figure 2A,B). Otherwise, nuclear lamin B expression was increased in glioma cells (Figure 2A,C).
Immunofluorescence and Western blot demonstrated that nucleocytoplasmic shuttling of Dp71 protein
occurs in oncogenic conditions.
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Figure 2. Lamin B and Dys protein (A,B,C) and mRNA expression (D,E) in tumor and NHA cells. 
Western blotting analysis shows Dys cytoplasmic (C) expression in HBL52, U118MG, and GLI1, 
tumor cells compared with Dys nuclear (N) expression in NHA cells (A). The lamin B expression is 
only nuclear for the presence of equal total (T) and nuclear (N) bands (A). The quantification of Dys 
bands (B) shows a significantly lower level of Dys proteins in total (T), nuclear (N), and cytoplasmic 
(C), protein fractions of U118MG and GLI1 cells compared to NHA cells, while the total (T) and 
cytoplasmic (C) protein fraction increases in HBL52 cells compared to NHA cells (B). The 
quantification of lamin B bands (B) reveals a significantly higher level of lamin B proteins in total (T) 
and nuclear (N) protein fractions of U118MG and GLI1 cells compared to NHA cells (C). The bands 
Figure 2. Lamin B and Dys protein (A–C) and mRNA expression (D,E) in tumor and NHA cells.
Western blotting analysis shows Dys cytoplasmic (C) expression in HBL52, U118MG, and GLI1, tumor
cells compared with Dys nuclear (N) expression in NHA cells (A). The lamin B expression is only
nuclear for the presence of equal total (T) and nuclear (N) bands (A). The quantification of Dys bands
(B) shows a significantly lower level of Dys proteins in total (T), nuclear (N), and cytoplasmic (C),
protein fractions of U118MG and GLI1 cells compared to NHA cells, while the total (T) and cytoplasmic
(C) protein fraction increases in HBL52 cells compared to NHA cells (B). The quantification of lamin B
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bands (B) reveals a significantly higher level of lamin B proteins in total (T) and nuclear (N) protein
fractions of U118MG and GLI1 cells compared to NHA cells (C). The bands are representative of three
independent experiments in triplicate for each protein, and β-actin was used as a housekeeping gene.
The data are expressed as proteins/β-actin ratio ± SEM. The Dys mRNA expression analysis by real-time
PCR (D) shows a significant increase of Dys mRNA levels in HBL52 cells and a decrease in U118MG
and GLI1 cells as compared with the control NHA cells (D). The lamin B mRNA expression analysis by
real-time PCR (E) shows a significant increase of lamin B mRNA levels in U118MG and GLI1 cells as
compared with the control NHA cells (E). (* p < 0.05 all groups vs. NHA group; ** p < 0.01 all groups
vs. NHA group; *** p < 0.001 all groups vs. NHA group).
Real-time quantitative PCR was performed to determine the Dp71 and lamin B mRNA levels in
glioblastoma cells. Dp71 expression was lower in U118MG and in GLI1 cells, and increased in HBL52
cells compared to the controls (Figure 2D). The increased lamin B mRNA levels were only detected in
U118MG and GLI1 cells (Figure 2E).
2.3. Decreased Dp71 Expression in Glioblastoma Bioptic Specimens and Correlation with the Ki-67 Tumor
Proliferative Index
Immunohistochemistry analyses were carried out on meningioma and glioblastoma specimens
(Figure 3A–E). Dp71 was localized prevalently in the nucleus of the control sections (Figure 3A).
In meningioma, a strong cytoplasmic Dp71 expression was observed (Figure 3B) while, in glioblastoma,
cytoplasmic localization was associated with a significant reduction of Dp71 expression (Figure 3C,D)
compared with meningioma (Figure 3B) and the controls (Figure 3A). Morphometric analysis showed
an overexpression of Dp71 protein in meningioma and a reduction in glioblastoma (Figure 3E).
Furthermore, we correlated Dp71 expression with the Ki-67 tumor proliferative index in glioblastoma
specimens. As shown in Table 1, a higher expression was found in patients with a higher Ki-67 index,
suggesting that Dp71 expression is associated with cell proliferation.
Table 1. Clinical and anatomical features of glioblastoma patients and Ki-67 tumor proliferative index.
Case Sex Age (Years) Tumor Location Ki-67 Dp71 Dystrophin Isoform(Dys) Protein Expression
1 M 54 Parieto-occipital lobe 38%
2 M 60 Temporo-parietal lobe 34% +
3 F 81 Left frontal lobe 45%
4 F 42 Left temporal lobe 30% +
5 M 58 Talamo 18% ++
6 M 68 Right parieto-occipital lobe 40%
7 M 60 Frontal lobe 25% ++
8 F 65 Left fronto-insular 50%
9 M 38 Temporal lobe 80%
10 M 48 Parieto-occipital lobe 60%
11 M 45 Left temporal lobe 25% ++
12 M 81 Left frontal lobe 28% +
13 F 65 Right parieto-occipital lobe 15% ++
14 M 45 Frontal lobe 60%
15 M 42 Right temporal lobe 30% +
16 M 66 Frontal lobe 18% ++
17 F 57 Right temporal lobe 40%
18 M 65 Frontal lobe 40%
19 F 54 Left parieto-occipital lobe 13% +++
20 M 73 Left parietal lobe 60%
21 M 64 Left temporo-insular 25% +
22 M 60 Right parietal lobe 50%
23 F 58 Temporal lobe 30% ++
24 F 76 Left temporal lobe 15% +++
25 M 43 Right parieto-occipital lobe 30% +
26 M 61 Left frontal lobe 20% ++
27 F 50 Left parietal lobe 15% ++
28 M 46 Right temporo-insular 25% +
29 M 54 Occipital lobe 80%
30 M 74 Temporal lobe 60%
strong (+++), moderate (++), weak (+) or absent ( ).
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Figure 3. Dys immunohistochemistry analysis in the tumor (B–D) and control (A) bioptic specimens.
Strong nuclear staining is detectable in the control section (A) while a diffuse and intense cytoplasmic
signal is present in meningioma cells (B). Glioblastoma cells (C,D) show a light Dys cytoplasmic
expression with no nuclear staining. Morphometric analysis (E) shows a significant decrease of Dys
protein in glioblastoma cells compared to the meningioma and control ones, while the meningioma
section shows a significant increase of Dys protein level compared to the control section. (** p < 0.01 vs.
control; *** p < 0.001 vs. meningioma). Scale bar A,B,C,D: 20 µm.
3. Discussion
In this study, we have demonstrated, for the first time, a significant reduction of the Dp71 mRNA
and protein in glioblastoma cell lines and in cells isolated from human GBM bioptic specimens
compared with the astrocytic control cell line. There was subcellular reorganization with a cytoplasmic
and clustered expression pattern for Dp71 protein in glioblastoma cells and in meningioma cell lines as
compared with nuclear and diffuse signal localization in the control cell line, where Dp71 colocalized
with lamin B. These results confirm that, in normal conditions, Dp71 participates in nuclear architecture,
serving as scaffolding for nuclear processes [17].
Int. J. Mol. Sci. 2019, 20, 5429 7 of 12
In normal conditions, Dp71—linked with dystrophin-associated proteins (DAPs) as aquaporin-4
(AQP4), alpha/beta-dystroglycan complex, and agrin—is highly expressed by perivascular astrocytic
endfeet, where it controls the integrity and function of the blood–brain barrier [18].
An altered expression pattern of Dp71- and DAP-associated proteins was found in GBM [19].
AQP4 proteins are involved in cell migration, angiogenesis, and edema formation in human brain
tumors [20,21]. The α-dystroglycan (α-DG) protein may be involved in the progression of primary
brain tumors [22].
There are two Dp71 isoforms that are derived from alternative splicing of exon 78 that show
differential subcellular localization [23]. The Dp71d isoform, which includes the region encoded by
exon 78, exhibits a predominant nuclear localization, while the Dp71f isoform, harboring an alternative
31-amino acid C-terminal domain by the removal of exon 78, is exclusively cytoplasmic [23,24].
The finding of the same isoform in the cytoplasm of tumor cells indicates that Dp71 can shuttle
between the nucleus and cytoplasm as modulated by specific tumor stimuli [25]. The reduction in
Dp71 expression and subcellular reorganization with cluster formation in glioblastoma cells suggest
that Dp71 proteins have different nuclear and cytoplasmic functions.
Lamin B is an important member of the lamin protein family and is involved in crucial
nuclear processes, including nuclear morphology, heterochromatin organization, cell division,
and senescence [26–29]. The role of lamin B in cancer development and progression is unclear
and controversial. In this study, we demonstrated that lamin B was significantly overexpressed in
glioblastoma cell lines compared to controls.
The role of lamin B in cancer development and progression is controversial [30–32]. The expression
of lamin B is reduced in lung cancer, colon cancer, and gastric cancer [11,33,34], whereas its expression
is increased in prostate cancer, hepatocellular carcinoma, and pancreatic cancer [35–38]. Our data have
shown that lamin B expression was significantly increased on the nuclear envelope of the glioblastoma
cell line and patient glioma cells as compared with the controls. The change in lamin B expression was
not detected in the meningioma cell line, suggesting that its expression correlates with an increase in
glioma malignancy grade.
Finally, we demonstrated that decreased Dp71 protein in cells isolated from human bioptic
specimens were inversely correlated with the Ki-67 tumor proliferative index. The patients with higher
Ki-67 exhibited lower Dp71 expression.
4. Materials and Methods
4.1. Tissue Samples
Primary human brain bioptic specimens (30 grade IV glioblastomas, 10 meningiomas, and 5
healthy tissues) were retrospectively selected from the archive of the Section of Pathology of the
University of Torino, Medical School, and the Section of Pathology of the Department of Emergency
Surgery and Organ Transplantation of the University of Bari, Medical School (Table 1). All procedures
followed were in accordance with the ethical standards of the responsible committee on human
experimentation (institutional, n.555, 5 June 2018) and with the Helsinki Declaration of 1964.
All primary tumors were obtained from patients who had undergone no prior treatment (radiotherapy
or chemotherapy). The tumor types and stages were determined according to the World Health
Organization classification [39].
4.2. Cell Culture
The U118MG cell line was obtained from ATCC (American Tissue Culture Collection, Manassan,VA,
USA), HBL52 cell line from CLS (Cell Lines Service, GmbH, Eppelheim, Geramany), and NHA (Lonza
Group Ltd, Basel, Switzerland cat , CC-2565). The U118MG cells were cultured in DMEM plus 4.5 g/L
D-glucose (GIBCO by Thermo scientificTM, Waltham, MA, USA), while the HBL52 and NHA cells were
cultured in DMEM/F-12 (1:1) (GIBCO by Thermo scientificTM, Waltham, MA, USA) supplemented
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with 10% fetal bovine serum (FBS; GIBCO, by Thermo scientificTM, Waltham, MA, USA), 100 U/mL
penicillin, and 100 µg/mL streptomycin, and maintained at 37 ◦C in a 5% CO2 humidified atmosphere.
4.3. Establishment of Primary Culture
We obtained the primary culture from three patients with grade IV GBM. After surgical removal,
upon the approval of the institutional Ethics Committee, tumor specimens were placed in DMEM-F12
medium without serum, repeatedly washed with phosphate-buffered saline (PBS, Invitrogen, Carlsbad,
CA, USA), and then placed in a 30 mm Petri dish. The specimens were cut in 1–2 mm3 fragments
and transferred in a poly-D-lysine treated flask with a small amount of Dulbecco’s modified Eagle’s
medium/F12 medium (D-MEM/F12, GIBCO by Thermo scientificTM, Waltham, MA, USA) (1:1, v/v),
supplemented with 10% fetal bovine serum (FBS, GIBCO by Thermo scientificTM, Waltham, MA, USA),
100 U/mL penicillin, and 100 µg/mL streptomycin (PenStrep, GIBCO by Thermo scientificTM, Waltham,
MA, USA), in order to allow the fragments to adhere to the surface of the flask. The primary culture
was incubated at 37 ◦C in a 5% CO2 humidified atmosphere, and 5 mL of complete medium was
added 24 h later. After one week, the primary culture was washed with PBS to remove non-adherent
fragments. Then, fresh medium, pre-warmed at 37 ◦C, was added. These procedures were repeated
every 3 days until the primary culture reached local confluence. Then, the cells were treated with 0.05%
trypsin (GIBCO by Thermo scientificTM, Waltham, MA, USA) and 0.02% EDTA (GIBCO by Thermo
scientificTM, Waltham, MA, USA), washed with PBS, and transferred into a T-75 flask without biocoat
containing the complete medium DMEM/F12.
4.4. Real-Time PCR
RNA was extracted from cells using an RNeasy Mini Kit (Qiagen, Germantown, MD, USA),
which was then used to synthesize the first strand c-DNA with the IScript cDNA Synthesis kit (Bio-Rad
Laboratories, Hercules, CA, USA), according to the manufacturer’s instructions. cDNA was amplified
with the iTaq SYBR Green Supermix (Bio-Rad Laboratories, Hercules, CA, USA). PCR amplification
and real-time detection were performed with the Chromo4 Real-Time PCR Detection System (Bio-Rad
Laboratories, Hercules, CA, USA). The expression of mRNA for Dp71 and lamin B was evaluated by
real-time PCR and the samples were normalized to cyclophilin A as a housekeeping gene. The primer
sequences are reported in Table 2. The analysis was performed with Bio-Rad CFX manager 3.1 software.
Table 2. Biorad primer PCR.
Gene Code
Dys qHsaCID0010707
Lamin B qHsaC1D0014822
Ciclophylin A qHsaCED0038620
Dys = Dp71 dystrophin isoform.
4.5. Western Blotting
To obtain total protein, extract tumors and control cells were homogenized in a lysis buffer
(cod. 89900, Thermo Scientific Rockford, IL, USA) and protease inhibitors were incubated three
times at −20 ◦C for 10 min. The cells were centrifuged at 14,000 rpm for 20 min and the supernatant
was collected. Moreover, harvested tumor and control cells were fractionated into cytoplasmic and
nuclear fractions using a nuclear and cytoplasmic extraction kit (NE-PERTM Nuclear and Cytoplasmic
Extraction Reagent, Thermo Fisher Scientific INC., Rockford, IL, USA). The protein concentration was
determined using the detergent-compatible Bio-Rad DC protein assay (Bio-Rad Laboratories, Hercules,
CA, USA). For immunoblotting, 30 mg per lane of protein extract was solubilized in Laemmli buffer,
boiled at 90 ◦C for 5 min, and resolved on Mini-Protean TGX Precast gels (cod. 456-1104, Bio-Rad
Laboratories, Hercules, CA, USA). Thereafter, the proteins were electrotransferred to a nitrocellulose
membrane (Trans Blot Turbo Transfer Pack cod. 170-4158, Bio-Rad Laboratories). The blots were
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blocked with a PBS blocking buffer containing 5% nonfat dry milk for 1 h and incubated overnight at
4 ◦C with the following primary antibodies: Dys, lamin B, and β-actin (Table 3). After the primary
antibody treatment, the membranes were washed 4 × 5 min each at room temperature in PBS with 0.1%
Tween-20 before the addition of secondary antibodies. The PBS and 0.1% Tween-20-diluted secondary
antibodies (anti-mouse and -rabbit) were IRDye labeled (800 CW) (LI-COR Biosciences, Lincoln, NE,
USA). For immunoblotting analysis, the LI-COR Odyssey infrared imaging system was used (LI-COR
Biosciences, Lincoln, NE, USA). The Western blot images were analyzed by imaging densitometry
using ImageJ and quantified through normalization with actin and expressed as optical density mm2.
The images are representative of three independent experiments performed in triplicate.
Table 3. Antibodies used for immunofluorescence (IF)/ immunohistochemistry (IH)/western blot (WB).
Protein Catalog Number Species IH Diluition IF Dilution WB Diluition Source
Dys NCL-DYS2 mouse 1:5 1:10 1:100 Novacastra-Leica
Lamin B1 PA5-19468 rabbit 1:100 1:100 Thermo Fischer
Actin Sc-47778 mouse 1:1000 SantaCruz-Bio
Alexa fluor 488 antirabbit A11034 goat 1:300 Invitrogen
Alexa fluor 555 antimouse A32727 goat 1:900 Invitrogen
IRDye 800CW antirabbit 926-32211 goat 1:7000 LI-COR
IRDye 800CW antimouse 926-32210 goat 1:7000 LI-COR
Dys = Dp71 dystrophin isoform.
4.6. Dual Immunofluorescence Confocal Laser Scanning Microscopy
The tumor and control cells were fixed in 4% paraformaldehyde (PFA), rinsed with
phosphate-buffered saline (PBS, cod. P4417, Sigma-Aldrich, St. Louis, MO, USA) and then exposed to
primary antibodies diluted in PBS with 0.2% BSA (Table 3). Then, the cells were incubated for 45 min
with the corresponding secondary antibodies at 37 ◦C (Table 3), and, following washing, they were
incubated for 20 min with 0.01% TO-PRO-3 (Invitrogen, Carlsbad, CA, USA) for nuclear staining, and
mounted in Vectashield (Vector Laboratories, Burlingame, CA, USA). The cells were examined under
a Leica TCS SP2 (Leica, Wetzlar, Germany) confocal laser scanning microscope using 40× and 63×
objective lenses with either 1× or 2× zoom factors. A sequential scan procedure was applied during
image acquisition of the two fluorophores. Confocal images were taken at 200 nm intervals through
the z axis of the section. The images from individual optical planes and multiple serial optical sections
were analyzed, digitally recorded, and stored as TIFF files using Adobe Photoshop software (Adobe
Systems Inc. San Jose, CA, USA).
4.7. Dys Immunohistochemistry
Four-micrometer-thick, 4% PFA-fixed and paraffin-embedded histological sections collected on
poly-L-lysine-coated slides (cod. J2800AMNZ, Gerhard Menzel, Germany) were deparaffinized and
rehydrated in a xylene-graded alcohol scale and then rinsed for 10 min in PBS. The sections were
heated in a solution of sodium citrate pH 6.0 (cod. S1699, Dako Corporation, Milano, Italy) once the
temperature had reached 98 ◦C in a water bath for 20 min and, after washing in TBS/Triton, were
kept for 10 min in a Dual Endogenous Enzyme Block buffer (Code S2003, Dako Corporation, Milano,
Italy). Afterwards, the sections were exposed to Dys primary unconjugated antibodies (see Table 3)
diluted in Dako antibody diluent (cod. S3022, Dako Corporation, Milano, Italy) for 30 min at 4 ◦C.
Immunodetection was performed with Dako REAL™ Detection System, Alkaline Phosphatase/RED
(Cod.K5005, Dako Corporation, Milano, Italy). Thereafter, the sections were counterstained with
Mayer’s hematoxylin and mounted in synthetic medium. The specific preimmune serum (Dako
Corporation, Milano, Italy, in place of the primary antibodies, served as a negative control.
4.8. Morphometric Analysis
Morphometric analysis was performed by two independent observers on ten randomly selected
fields observed at 63× magnification for immunofluorescence reactions by using CellˆF image analysis
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software (Olympus Italia, Rozzano, Italy). For immunohistochemistry, morphometric analysis was
performed on 10 sections from each experimental group by means of five cases per group and using
image analysis software (Olympus Italia, Rozzano Italy).
4.9. Statistical Analysis
The data are reported as means ± SD. Two-way Anova was used for grouped analyses and
Bonferroni post-test was used to compare all groups vs. control group. The GraphPad Prism 5.0
statistical package (GraphPad Software, San Diego, CA, USA) was used for the analysis and p < 0.05
values were considered statistically significant.
5. Conclusions
These data suggest that lower expression of Dp71 is correlated with tumor progression in
glioblastoma multiforme and that its expression is associated with lamin B overexpression and a high
Ki-67 proliferative index.
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